Annie Martin


Annie Martin, SVP, Global Head of Precision Medicine, Novartis

SVP, Global Head of Precision Medicine, Novartis (since Feb 2016)

Dr. Anne-Marie Martin, also known as Annie, Ph.D. has been Vice President and Head of Biomarker Research and Development of Adaptimmune Therapeutics plc since May 2015. Dr. Martin has nearly 15 years of clinical development and biomarker experience with Pennsylvania Hospital/UPHS and GSK Oncology to Adaptimmune. She began her pharmaceutical career at GSK in 2005, and then held positions of increasing seniority with GSK Oncology, culminating in her tenure as Head of Precision Medicine and Diagnostics, GSK Oncology R&D and Head of GSK Oncology's Molecular Medicine Unit. During her tenure, she had responsibility for clinical translational research and companion diagnostic (cDx) development for late clinical phase development. She led a global team responsible for the precision medicine strategy in Oncology to deliver all translational research into pipeline opportunities, accounting for over 10 clinical assets and an additional five assets in first-in-human testing, and led the development of the cDx that supported the approvals of Tafinlar® (dabrafenib) and Mekinist™ (trametinib). During her tenure, Dr. Martin contributed to three NDAs and five sNDAs. Dr. Martin has a Ph.D. in Immunogenetics from MCP-Hahnemann University, Philadelphia, PA, and was a postdoctoral Fellow and adjunct assistant professor at the University of Pennsylvania.

Listen to the interview with Annie (published August 2017) https://mendelspod.com/podcasts/thermo-pfizer-and-novartis-pull-first-ng...



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup